The CJC-1295 + Ipamorelin blend is one of the most recognized combinations in growth hormone secretagogue research. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), designed to have an extended half-life compared to native GHRH. Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that stimulates GH release through the ghrelin receptor. Together, they're used in research models studying how these two complementary pathways interact.

Research on CJC-1295 has investigated its ability to sustain elevated GH-releasing activity in pre-clinical models, while Ipamorelin studies have focused on its selectivity — it appears to stimulate GH release with less impact on cortisol and prolactin compared to earlier-generation GHRPs. The combination is frequently used in protocols exploring GH secretion dynamics and pituitary receptor signaling.

This peptide blend is used in laboratory settings where researchers are studying the additive or synergistic effects of GHRH and GHRP co-administration. It's a practical preparation for labs exploring endocrine signaling without needing to prepare and dose two separate peptides.

myPEPT supplies this GH secretagogue blend at ≥99% purity per component, with a Certificate of Analysis from third-party testing. Shipped lyophilized across the EU in research-grade packaging.

What researchers should know: This blend is for laboratory research use only and is not approved for human use. It is not a medicinal product. Researchers should follow all applicable institutional and regulatory guidelines when working with GH-related peptides.